Nature Communications (May 2022)
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
- Xintao Qiu,
- Nadia Boufaied,
- Tarek Hallal,
- Avery Feit,
- Anna de Polo,
- Adrienne M. Luoma,
- Walaa Alahmadi,
- Janie Larocque,
- Giorgia Zadra,
- Yingtian Xie,
- Shengqing Gu,
- Qin Tang,
- Yi Zhang,
- Sudeepa Syamala,
- Ji-Heui Seo,
- Connor Bell,
- Edward O’Connor,
- Yang Liu,
- Edward M. Schaeffer,
- R. Jeffrey Karnes,
- Sheila Weinmann,
- Elai Davicioni,
- Colm Morrissey,
- Paloma Cejas,
- Leigh Ellis,
- Massimo Loda,
- Kai W. Wucherpfennig,
- Mark M. Pomerantz,
- Daniel E. Spratt,
- Eva Corey,
- Matthew L. Freedman,
- X. Shirley Liu,
- Myles Brown,
- Henry W. Long,
- David P. Labbé
Affiliations
- Xintao Qiu
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Nadia Boufaied
- Cancer Research Program, Research Institute of the McGill University Health Centre
- Tarek Hallal
- Cancer Research Program, Research Institute of the McGill University Health Centre
- Avery Feit
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Anna de Polo
- Cancer Research Program, Research Institute of the McGill University Health Centre
- Adrienne M. Luoma
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School
- Walaa Alahmadi
- Cancer Research Program, Research Institute of the McGill University Health Centre
- Janie Larocque
- Cancer Research Program, Research Institute of the McGill University Health Centre
- Giorgia Zadra
- Departments of Oncologic Pathology and Pathology, Dana-Farber Cancer Institute and Brigham’s Women Hospital
- Yingtian Xie
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Shengqing Gu
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Qin Tang
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Yi Zhang
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Sudeepa Syamala
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Ji-Heui Seo
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Connor Bell
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Edward O’Connor
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Yang Liu
- Decipher Biosciences
- Edward M. Schaeffer
- Department of Urology, Northwestern University
- R. Jeffrey Karnes
- Department of Urology, Mayo Clinic
- Sheila Weinmann
- Center for Health Research, Kaiser Permanente Northwest
- Elai Davicioni
- Decipher Biosciences
- Colm Morrissey
- Department of Urology, University of Washington
- Paloma Cejas
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Leigh Ellis
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center
- Massimo Loda
- Department of Pathology and Laboratory Medicine, Weil Cornell Medicine, New York Presbyterian-Weill Cornell Campus
- Kai W. Wucherpfennig
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School
- Mark M. Pomerantz
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Daniel E. Spratt
- Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine
- Eva Corey
- Department of Urology, University of Washington
- Matthew L. Freedman
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- X. Shirley Liu
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Myles Brown
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- Henry W. Long
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute
- David P. Labbé
- Cancer Research Program, Research Institute of the McGill University Health Centre
- DOI
- https://doi.org/10.1038/s41467-022-30257-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
The role of MYC in transcriptional reprogramming in prostate cancer remains poorly characterized. Here, MYC overexpression antagonizes the canonical AR transcriptional program leading to prostate tumor initiation and progression by disrupting transcriptional pause release at AR-regulated genes.
